Q3 2024 Whitepaper: China's Dermatological Drugs Market Analysis

Key Finding 1

China's online dermatological drugs market reached CN¥ 5.69 billion in 2023 (+2.8% YoY), with prescription (RX) drug share rising steadily as e-prescription policies reshape the channel mix.

The three-year online market expansion from CN¥ 4.02 billion in 2021 to CN¥ 5.69 billion in 2023 has been driven by the convenience of online purchasing, growing public health awareness, consumer preference for privacy when buying sensitive medications, and the proliferation of online consultations and e-prescriptions. For January-July 2024, sales reached CN¥ 3.86 billion (+20.4% YoY), signaling continued acceleration. The RX share increased from 27.4% in 2023 to 28.7% in January-July 2024, driven by prescription outflow policies and regulations enabling online RX drug sales.

Key Finding 2

The global dermatological drugs market is projected to reach US$ 71.66 billion by 2029, growing at a 9.67% CAGR, while China's domestic market reached CN¥ 25.7 billion in 2023 with online channels expanding as a share of total.

China's domestic dermatological drug market has grown from CN¥ 20.1 billion (offline CN¥ 18.6 billion + online CN¥ 1.5 billion) in 2018 to CN¥ 25.7 billion (offline CN¥ 21.1 billion + online CN¥ 4.6 billion) in 2023. The online channel share has more than tripled from 7.5% to 17.9% over this period, and is projected to reach 26.5% by 2027. This structural channel migration represents one of the most significant distribution shifts in China's pharmaceutical sector.

Key Finding 3

Dermatitis and eczema drugs dominate the RX segment with 30.36% market share and +48.5% YoY growth, while antifungal drugs (+28.4% YoY) and wart/herpes medications emerge as high-growth sub-categories.

The prescription dermatological market shows clear growth concentration: dermatitis-eczema drugs captured CN¥ 3.36 billion in January-July 2024 sales (up from CN¥ 2.26 billion YoY), reflecting surging consumer demand for symptom relief. Meanwhile, antifungal drugs reached CN¥ 1.32 billion (+28.4% YoY), and wart/herpes medications demonstrated the fastest growth trajectory. Volume growth is outpacing price growth, with mainstream drug average prices declining while sales volume drives market expansion.

Key Finding 4

The pet medication market reached CN¥ 1.83 billion in January-July 2024 (+8.0% YoY), with deworming products leading at CN¥ 613 million while ear (+44.9% YoY) and oral care medications (+46.4% YoY) emerge as the fastest-growing segments.

Taobao/Tmall (淘系) platforms dominate with CN¥ 3.23 billion in cumulative sales (2023-2024), followed by JD.com (京东) at CN¥ 1.24 billion and Douyin (抖音) at CN¥ 320 million. The pet medication market demonstrates both scale and structural growth, as rising pet ownership and increasing humanization of pets drive demand beyond core deworming products into specialized categories like ear care, oral health, and dermatological treatments.